Insider · CIK 0001397266

Fust Matthew K

CIK 0001397266 Name as filed on the most recent filing

Filed as Fust Matthew K (41)

53 transaction lines · from 41 filings · filed 2010-01-07 to 2025-09-30 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

53 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-27 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2025-09-26 S, Open-market sale Crinetics Pharmaceuticals, Inc.CRNX 716,000, disposed Open Form 4 filing 0001658247-25-000010
2024-10-18 S, Open-market sale Neumora Therapeutics, Inc.NMRA 239,319, disposed Open Form 4 filing 0001610717-24-000511
2024-10-17 S, Open-market sale Neumora Therapeutics, Inc.NMRA 131,643, disposed Open Form 4 filing 0001610717-24-000511
2024-03-20 S, Open-market sale Crinetics Pharmaceuticals, Inc.CRNX 4 lines 2,648,150, disposed Open Form 4 filing 0001209191-24-005060
2024-03-07 S, Open-market sale Ultragenyx Pharmaceutical Inc.RARE 3 lines 620,443, disposed Open Form 4 filing 0000950170-24-029040
2022-07-13 S, Open-market sale Crinetics Pharmaceuticals, Inc.CRNX 119,455, disposed Open Form 4 filing 0001209191-22-042245
2021-11-04 S, Open-market sale Atara Biotherapeutics, Inc.ATRA 260,403, disposed Open Form 4 filing 0001567619-21-019403
2021-11-01 S, Open-market sale Crinetics Pharmaceuticals, Inc.CRNX 228,327, disposed Open Form 4 filing 0001209191-21-062728
2021-09-08 S, Open-market sale Crinetics Pharmaceuticals, Inc.CRNX 154,173, disposed Open Form 4 filing 0001209191-21-055314
2021-07-26 S, Open-market sale Crinetics Pharmaceuticals, Inc.CRNX 97,950, disposed Open Form 4 filing 0001209191-21-048375
2021-07-19 S, Open-market sale Crinetics Pharmaceuticals, Inc.CRNX 97,500, disposed Open Form 4 filing 0001209191-21-047402
2021-07-12 S, Open-market sale Crinetics Pharmaceuticals, Inc.CRNX 103,550, disposed Open Form 4 filing 0001209191-21-046554
2020-07-06 S, Open-market sale Ultragenyx Pharmaceutical Inc.RARE 556,290, disposed Open Form 4 filing 0001209191-20-041644
2020-07-01 S, Open-market sale Ultragenyx Pharmaceutical Inc.RARE 425,000, disposed Open Form 4 filing 0001209191-20-040945
2020-05-18 S, Open-market sale Ultragenyx Pharmaceutical Inc.RARE 140,625, disposed Open Form 4 filing 0001209191-20-030709
2020-04-22 S, Open-market sale Ultragenyx Pharmaceutical Inc.RARE 121,875, disposed Open Form 4 filing 0001209191-20-025550
2019-12-24 S, Open-market sale Dermira, Inc.DERM 45,000, disposed Open Form 4 filing 0001562180-19-006267
2019-12-16 S, Open-market sale Crinetics Pharmaceuticals, Inc.CRNX 78,750, disposed Open Form 4 filing 0001209191-19-061184
2019-12-12 S, Open-market sale Dermira, Inc.DERM 36,000, disposed Open Form 4 filing 0001562180-19-006079
2019-09-12 S, Open-market sale Dermira, Inc.DERM 52,636, disposed Open Form 4 filing 0001562180-19-004818
2019-02-06 S, Open-market sale MacRogenics IncMGNX 203,427, disposed Open Form 4 filing 0001125345-19-000018
2018-10-19 S, Open-market sale Dermira, Inc.DERM 55,000, disposed Open Form 4 filing 0001562180-18-004253
2018-05-30 S, Open-market sale Ultragenyx Pharmaceutical Inc.RARE 454,969, disposed Open Form 4 filing 0001209191-18-034278
2018-05-14 S, Open-market sale Atara Biotherapeutics, Inc.ATRA 535,301, disposed Open Form 4 filing 0001209191-18-030726
2014-11-25 P, Open-market purchase Dermira, Inc.DERM 100,604, acquired Open Form 4 filing 0001140361-14-043609
2014-01-30 P, Open-market purchase Ultragenyx Pharmaceutical Inc.RARE 105,000, acquired Open Form 4 filing 0001209191-14-006664
2013-08-08 S, Open-market sale Onyx Pharmaceuticals IncONXX 319,499, disposed Open Form 4 filing 0001179110-13-013051
2013-07-26 S, Open-market sale Onyx Pharmaceuticals IncONXX 788,612, disposed Open Form 4 filing 0001179110-13-012260
2013-07-02 S, Open-market sale Onyx Pharmaceuticals IncONXX 2 lines 205,973, disposed Open Form 4 filing 0001179110-13-011583
2013-05-13 S, Open-market sale Onyx Pharmaceuticals IncONXX 2 lines 1,008,598, disposed Open Form 4 filing 0001179110-13-008495
2013-04-15 S, Open-market sale Onyx Pharmaceuticals IncONXX 128,167, disposed Open Form 4 filing 0001179110-13-006838
2013-04-01 S, Open-market sale Onyx Pharmaceuticals IncONXX 2 lines 332,575, disposed Open Form 4 filing 0001179110-13-006440
2013-02-28 S, Open-market sale Onyx Pharmaceuticals IncONXX 1,156,800, disposed Open Form 4 filing 0001179110-13-004074
2013-01-10 S, Open-market sale Onyx Pharmaceuticals IncONXX 2 lines 865,582, disposed Open Form 4 filing 0001179110-13-000808
2012-08-06 S, Open-market sale Onyx Pharmaceuticals IncONXX 3 lines 1,578,267, disposed Open Form 4 filing 0001209191-12-041040
2012-07-25 S, Open-market sale Onyx Pharmaceuticals IncONXX 385,171, disposed Open Form 4 filing 0001209191-12-039432
2012-03-02 S, Open-market sale Onyx Pharmaceuticals IncONXX 22,212, disposed Open Form 4 filing 0001209191-12-016274
2012-01-06 S, Open-market sale Onyx Pharmaceuticals IncONXX 77,750, disposed Open Form 4 filing 0001209191-12-003129
2011-11-18 S, Open-market sale Onyx Pharmaceuticals IncONXX 32,989, disposed Open Form 4 filing 0001209191-11-057407

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase
Relationships on this page
D, Director
Director
O, Officer
Officer

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 2
  • Open-market sale 51
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Fust Matthew K, insider transactions. Retrieved 2026-08-27 from https://ebomi.com/insider/0001397266

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.